497 related articles for article (PubMed ID: 30845999)
1. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
[TBL] [Abstract][Full Text] [Related]
2. A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
Matossian MD; Burks HE; Bowles AC; Elliott S; Hoang VT; Sabol RA; Pashos NC; O'Donnell B; Miller KS; Wahba BM; Bunnell BA; Moroz K; Zea AH; Jones SD; Ochoa AC; Al-Khami AA; Hossain F; Riker AI; Rhodes LV; Martin EC; Miele L; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2018 Jun; 169(2):381-390. PubMed ID: 29392581
[TBL] [Abstract][Full Text] [Related]
3. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.
Matossian MD; Chang T; Wright MK; Burks HE; Elliott S; Sabol RA; Wathieu H; Windsor GO; Alzoubi MS; King CT; Bursavich JB; Ham AM; Savoie JJ; Nguyen K; Baddoo M; Flemington E; Sirenko O; Cromwell EF; Hebert KL; Lau F; Izadpanah R; Brown H; Sinha S; Zabaleta J; Riker AI; Moroz K; Miele L; Zea AH; Ochoa A; Bunnell BA; Collins-Burow BM; Martin EC; Burow ME
Clin Transl Oncol; 2022 Jan; 24(1):127-144. PubMed ID: 34370182
[TBL] [Abstract][Full Text] [Related]
4. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
[TBL] [Abstract][Full Text] [Related]
5. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
7. Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models.
Sabol RA; Bowles AC; Côté A; Wise R; O'Donnell B; Matossian MD; Hossain FM; Burks HE; Del Valle L; Miele L; Collins-Burow BM; Burow ME; Bunnell BA
Breast Cancer Res; 2019 May; 21(1):67. PubMed ID: 31118047
[TBL] [Abstract][Full Text] [Related]
8. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.
Damelin M; Bankovich A; Park A; Aguilar J; Anderson W; Santaguida M; Aujay M; Fong S; Khandke K; Pulito V; Ernstoff E; Escarpe P; Bernstein J; Pysz M; Zhong W; Upeslacis E; Lucas J; Lucas J; Nichols T; Loving K; Foord O; Hampl J; Stull R; Barletta F; Falahatpisheh H; Sapra P; Gerber HP; Dylla SJ
Clin Cancer Res; 2015 Sep; 21(18):4165-73. PubMed ID: 26015513
[TBL] [Abstract][Full Text] [Related]
9. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
10. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
12. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
Turner TH; Alzubi MA; Sohal SS; Olex AL; Dozmorov MG; Harrell JC
Breast Cancer Res Treat; 2018 Jul; 170(2):221-234. PubMed ID: 29532339
[TBL] [Abstract][Full Text] [Related]
13. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
14. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
15. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
Gómez-Miragaya J; Palafox M; Paré L; Yoldi G; Ferrer I; Vila S; Galván P; Pellegrini P; Pérez-Montoyo H; Igea A; Muñoz P; Esteller M; Nebreda AR; Urruticoechea A; Morilla I; Pernas S; Climent F; Soler-Monso MT; Petit A; Serra V; Prat A; González-Suárez E
Stem Cell Reports; 2017 May; 8(5):1392-1407. PubMed ID: 28457887
[TBL] [Abstract][Full Text] [Related]
16. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
[TBL] [Abstract][Full Text] [Related]
17. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
18.
Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
20. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
[No Abstract] [Full Text] [Related]
[Next] [New Search]
